Literature DB >> 18757267

RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer.

Joyce A O'Shaughnessy1, Adam M Brufsky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18757267     DOI： 10.3816/CBC.2008.n.045

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN： 1526-8209            Impact factor:   3.225


× No keyword cloud information.
  10 in total

1.  Deciphering the anticancer mechanisms of sunitinib.

Authors:  Sumanta Kumar Pal; Robert A Figlin; Hua Yu
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

Review 2.  Bevacizumab in the treatment of metastatic breast cancer: friend or foe?

Authors:  Alberto J Montero; Mauricio Escobar; Gilberto Lopes; Stefan Glück; Charles Vogel
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

3.  Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis.

Authors:  M Di Salvatore; L Lo Giudice; E Rossi; C Santonocito; G Nazzicone; M G Rodriquenz; S Cappuccio; A Inno; P Fuso; A Orlandi; A Strippoli; E Capoluongo; A Astone; A Cassano; C Barone
Journal:  Clin Transl Oncol       Date:  2015-07-04       Impact factor: 3.405

Review 4.  Targeted therapies for breast cancer.

Authors:  Michaela J Higgins; José Baselga
Journal:  J Clin Invest       Date:  2011-10-03       Impact factor: 14.808

5.  Bevacizumab for advanced breast cancer: hope, hype, and hundreds of headlines.

Authors:  Michael Fralick; Monali Ray; Christina Fung; Christopher M Booth; Ranjeeta Mallick; Mark J Clemons
Journal:  Oncologist       Date:  2013-09-26

6.  Bevacizumab in metastatic breast cancer: when may it be used?

Authors:  Shari B Goldfarb; Clifford Hudis; Maura N Dickler
Journal:  Ther Adv Med Oncol       Date:  2011-03       Impact factor: 8.168

Review 7.  Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review.

Authors:  Susan E Pories; Gerburg M Wulf
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-06-21

8.  Bevacizumab in the treatment of HER2-negative breast cancer.

Authors:  Vito Lorusso
Journal:  Biologics       Date:  2008-12

9.  Update on triple-negative breast cancer: prognosis and management strategies.

Authors:  Olivier Brouckaert; Hans Wildiers; Giuseppe Floris; Patrick Neven
Journal:  Int J Womens Health       Date:  2012-09-24

10.  Comment on 'The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer'.

Authors:  D Kitchen; M O'Brien; B Hughes; I Gill; S Rumbles; P Ellis; J Stebbing
Journal:  Br J Cancer       Date:  2013-06-11       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.